The impact of 18 FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study-Reference-Cited by-同舟云学术

The impact of 18 FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study

Published:2002-02 Issue:2 Volume:52 Page:339-350
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Mah Katherine,Caldwell Curtis B,Ung Yee C,Danjoux Cyril E,Balogh Judith M,Ganguli S.Nimu,Ehrlich Lisa E,Tirona Romeo

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference38 articles.

1. Dose escalation for non-small cell lung cancer using conformal radiation therapy;Robertson;Int J Radiat Oncol Biol Phys,1997

2. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer;Armstrong;Radiother Oncol,1997

3. Preliminary results of 92.4 Gy or more for non-small cell lung cancer;Henning;Int J Radiat Oncol Biol Phys,2000

4. Observer variation in contouring gross tumour volume in patients with poorly-defined non-small cell lung tumours on CT;Caldwell;Int J Radiat Oncol Biol Phys,2001

5. Evaluation of a target contouring protocol for 3D conformal radiotherapy in non-small cell lung cancer;Senan;Radiother Oncol,1999

Cited by 269 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiotherapy for primary lung cancer;Cancer/Radiothérapie;2022-02

2. Intensity-Modulated Radiation Therapy and Volumetric Modulated Arc Therapy for Lung Cancer;Medical Radiology;2022

3. PET Diagnosis and Response Monitoring in Oncology;Molecular Imaging;2021

4. Comparison of Different Methods for Delineation of ¹⁸F-FDG PET-Positive Tissue for Target Volume Definition in Radiotherapy of Patients with Non-Small Cell Lung Cancer;J NUCL MED;2020

5. Quelles stratégies thérapeutiques pour les CBNPC de stade IIIA (T1-T3N2) ?;Revue des Maladies Respiratoires Actualités;2018-10